GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » 14-Day RSI

Lipocine (Lipocine) 14-Day RSI

: 50.53 (As of Today)
View and export this data going back to 2012. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-23), Lipocine's 14-Day RSI is 50.53.

The industry rank for Lipocine's 14-Day RSI or its related term are showing as below:

LPCN's 14-Day RSI is ranked worse than
84.62% of 1573 companies
in the Biotechnology industry
Industry Median: 40.96 vs LPCN: 50.53

Competitive Comparison

For the Biotechnology subindustry, Lipocine's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipocine 14-Day RSI Distribution

For the Biotechnology industry and Healthcare sector, Lipocine's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Lipocine's 14-Day RSI falls into.



Lipocine  (NAS:LPCN) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipocine  (NAS:LPCN) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Lipocine 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Lipocine's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipocine (Lipocine) Business Description

Traded in Other Exchanges
N/A
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.
Executives
Mahesh V. Patel director, officer: President and CEO C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono director 18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos director C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos officer: Chief Medical Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty officer: Principal Accounting Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi director C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown officer: EVP and CFO 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink director 2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass officer: EVP and Chief Commercial Offic 3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila officer: Chief Business Officer AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran officer: CTO and VP RandD C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell officer: VP Finance C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons officer: VP Corp Business Development 837 4TH AVE, SALT LAKE CITY UT 84103